358 related articles for article (PubMed ID: 31656201)
1. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis.
Cao T; Pan W; Sun X; Shen H
J Ovarian Res; 2019 Oct; 12(1):101. PubMed ID: 31656201
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis.
Carella A; Tejedor JR; García MG; Urdinguio RG; Bayón GF; Sierra M; López V; García-Toraño E; Santamarina-Ojeda P; Pérez RF; Bigot T; Mangas C; Corte-Torres MD; Sáenz-de-Santa-María I; Mollejo M; Meléndez B; Astudillo A; Chiara MD; Fernández AF; Fraga MF
Int J Cancer; 2020 Jan; 146(2):373-387. PubMed ID: 31211412
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
4. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer.
Zhou Q; Mei YD; Yang HJ; Tao YL
Future Oncol; 2021 May; 17(15):1889-1906. PubMed ID: 33728938
[No Abstract] [Full Text] [Related]
7. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.
Tian X; Han Y; Yu L; Luo B; Hu Z; Li X; Yang Z; Wang X; Huang W; Wang H; Zhang Q; Ma D
Cancer Biol Ther; 2017 Apr; 18(4):245-251. PubMed ID: 28346042
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.
Matondo A; Jo YH; Shahid M; Choi TG; Nguyen MN; Nguyen NNY; Akter S; Kang I; Ha J; Maeng CH; Kim SY; Lee JS; Kim J; Kim SS
Sci Rep; 2017 Aug; 7(1):9689. PubMed ID: 28851888
[TBL] [Abstract][Full Text] [Related]
10. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
12. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of S100 family mRNA expression in ovarian cancer.
Ma N; Zhu L; Yang L; Cui Y; Zhan Y
Cancer Biomark; 2019; 25(1):67-78. PubMed ID: 31033462
[TBL] [Abstract][Full Text] [Related]
14. Multi-Omics Analysis Identifying Key Biomarkers in Ovarian Cancer.
Li JY; Li CJ; Lin LT; Tsui KH
Cancer Control; 2020; 27(1):1073274820976671. PubMed ID: 33297760
[TBL] [Abstract][Full Text] [Related]
15. TET3 Mediates Alterations in the Epigenetic Marker 5hmC and Akt pathway in Steroid-Associated Osteonecrosis.
Zhao J; Ma XL; Ma JX; Sun L; Lu B; Wang Y; Xing GS; Wang Y; Dong BC; Xu LY; Kuang MJ; Fu L; Bai HH; Ma Y; Jin WL
J Bone Miner Res; 2017 Feb; 32(2):319-332. PubMed ID: 27627619
[TBL] [Abstract][Full Text] [Related]
16. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract][Full Text] [Related]
17. Expression profiles and prognostic values of BolA family members in ovarian cancer.
Zhu M; Xiao S
J Ovarian Res; 2021 Jun; 14(1):75. PubMed ID: 34078439
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer.
Xie S; Shen C; Tan M; Li M; Song X; Wang C
Oncotarget; 2017 Apr; 8(16):27216-27239. PubMed ID: 28423713
[TBL] [Abstract][Full Text] [Related]
19. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
Zhou X; Teng L; Wang M
Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
[TBL] [Abstract][Full Text] [Related]
20. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
